|
G |
6430548M08Rikl |
RIKEN cDNA 6430548M08 gene like |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KIAA0513 mRNA Coumestrol results in decreased expression of KIAA0513 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:48,168,651...48,216,571
Ensembl chr19:48,198,209...48,216,575
|
|
G |
Aaas |
aladin WD repeat nucleoporin |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AAAS mRNA Coumestrol results in increased expression of AAAS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:133,464,315...133,483,961
Ensembl chr 7:133,464,315...133,483,961
|
|
G |
Aars1 |
alanyl-tRNA synthetase 1 |
increases expression |
ISO |
Coumestrol results in increased expression of AARS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
increases expression |
ISO |
Coumestrol results in increased expression of ABAT mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABCC5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ABCD3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Abce1 |
ATP binding cassette subfamily E member 1 |
increases expression |
ISO |
Coumestrol results in increased expression of ABCE1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:28,205,566...28,230,489
Ensembl chr19:28,205,555...28,230,489
|
|
G |
Abcf1 |
ATP binding cassette subfamily F member 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ABCF1 mRNA Coumestrol results in increased expression of ABCF1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:2,802,519...2,815,433
Ensembl chr20:2,802,488...2,815,433
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABCG1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ABCG1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abhd11 |
abhydrolase domain containing 11 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of ABHD11 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABHD11 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ABHD11 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:21,682,206...21,685,331
Ensembl chr12:21,682,202...21,685,398
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ABHD12 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd16a |
abhydrolase domain containing 16A, phospholipase |
decreases expression |
ISO |
Coumestrol results in decreased expression of ABHD16A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
|
|
G |
Abi1 |
abl-interactor 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ABI1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792
|
|
G |
Abraxas1 |
abraxas 1, BRCA1 A complex subunit |
decreases expression |
ISO |
Coumestrol results in decreased expression of ABRAXAS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:8,796,281...8,810,625
Ensembl chr14:8,796,266...8,810,622
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACAA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACAT2 mRNA Coumestrol results in increased expression of ACAT2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acbd3 |
acyl-CoA binding domain containing 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACBD3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACKR3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACLY mRNA Coumestrol results in increased expression of ACLY mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACOT4 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ACOT4 mRNA Coumestrol results in increased expression of ACOT4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of ACOT7 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACOT7 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ACOT7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ACSL3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acss3 |
acyl-CoA synthetase short-chain family member 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ACSS3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:42,241,261...42,450,209
Ensembl chr 7:42,242,652...42,450,230
|
|
G |
Acvr1 |
activin A receptor type 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ACVR1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:42,978,558...43,097,892
Ensembl chr 3:42,978,561...43,098,241
|
|
G |
Acyp1 |
acylphosphatase 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of ACYP1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACYP1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ACYP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:104,919,162...104,932,348
Ensembl chr 6:104,919,162...104,932,387
|
|
G |
Adat1 |
adenosine deaminase, tRNA-specific 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ADAT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:39,918,083...39,956,886
Ensembl chr19:39,918,227...39,956,883
|
|
G |
Add3 |
adducin 3 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ADD3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ADD3 mRNA Coumestrol results in increased expression of ADD3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124
|
|
G |
Adk |
adenosine kinase |
increases expression |
ISO |
Coumestrol results in increased expression of ADK mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA] |
CTD |
PMID:18310284 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Afap1 |
actin filament associated protein 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AFAP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:74,743,322...74,856,300
Ensembl chr14:74,743,320...74,856,263
|
|
G |
Aff4 |
ALF transcription elongation factor 4 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AFF4 mRNA Coumestrol results in decreased expression of AFF4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
Coumestrol binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agap1 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of AGAP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:90,039,720...90,475,196
Ensembl chr 9:90,039,605...90,470,958
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of AGO2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Agpat3 |
1-acylglycerol-3-phosphate O-acyltransferase 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of AGPAT3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:10,330,960...10,415,358
Ensembl chr20:10,384,507...10,415,358
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AGR2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AGR2 mRNA Coumestrol results in increased expression of AGR2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
|
|
G |
Agr3 |
anterior gradient 3, protein disulphide isomerase family member |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AGR3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AGR3 mRNA Coumestrol results in increased expression of AGR3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:52,643,391...52,666,638
Ensembl chr 6:52,643,391...52,666,638
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
increases expression |
ISO |
Coumestrol results in increased expression of AGTRAP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of AHCYL1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815
|
|
G |
Ahsa1 |
activator of Hsp90 ATPase activity 1 |
increases expression |
ISO |
Coumestrol results in increased expression of AHSA1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:106,913,296...106,921,347
Ensembl chr 6:106,913,530...106,921,345
|
|
G |
Ajuba |
ajuba LIM protein |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AJUBA mRNA Coumestrol results in decreased expression of AJUBA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of AKAP13 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AKAP13 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
decreases expression |
ISO |
Coumestrol results in decreased expression of ALCAM mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh16a1 |
aldehyde dehydrogenase 16 family, member A1 |
increases expression |
ISO |
Coumestrol results in increased expression of ALDH16A1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:95,626,727...95,639,808
Ensembl chr 1:95,613,558...95,640,131
|
|
G |
Aldh3b2 |
aldehyde dehydrogenase 3 family, member B2 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of ALDH3B2 mRNA Coumestrol results in decreased expression of ALDH3B2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:201,250,260...201,264,699
Ensembl chr 1:201,253,157...201,264,705 Ensembl chr 1:201,253,157...201,264,705
|
|
G |
Aldh3b3 |
aldehyde dehydrogenase 3 family, member B3 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with Resveratrol] results in decreased expression of ALDH3B2 mRNA Coumestrol results in decreased expression of ALDH3B2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:201,193,832...201,201,666
Ensembl chr 1:201,187,962...201,250,204
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of ALDH4A1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Alg6 |
ALG6, alpha-1,3-glucosyltransferase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ALG6 mRNA Coumestrol results in increased expression of ALG6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:114,404,972...114,454,440
Ensembl chr 5:114,405,010...114,454,439
|
|
G |
Alg8 |
ALG8, alpha-1,3-glucosyltransferase |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of ALG8 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ALG8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:151,684,344...151,704,310
Ensembl chr 1:151,684,396...151,704,302
|
|
G |
Alkbh7 |
alkB homolog 7 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ALKBH7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein; fulvestrant inhibits the reaction [[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein] |
CTD |
PMID:12650720 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Als2 |
alsin Rho guanine nucleotide exchange factor ALS2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ALS2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737
|
|
G |
Alyref |
Aly/REF export factor |
increases expression |
ISO |
Coumestrol results in increased expression of ALYREF mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:105,871,424...105,875,076
Ensembl chr10:105,871,306...105,875,069
|
|
G |
Amd1 |
adenosylmethionine decarboxylase 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of AMD1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AMD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AMD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:43,695,783...43,711,476
Ensembl chr20:43,697,237...43,711,476
|
|
G |
Amfr |
autocrine motility factor receptor |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of AMFR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:10,996,705...11,032,260
Ensembl chr19:10,996,099...11,032,247
|
|
G |
Ammecr1 |
AMMECR nuclear protein 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AMMECR1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AMMECR1 mRNA Coumestrol results in increased expression of AMMECR1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:106,465,982...106,571,382
Ensembl chr X:106,466,699...106,571,487
|
|
G |
Amotl2 |
angiomotin like 2 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of AMOTL2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AMOTL2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
increases expression |
ISO |
Coumestrol results in increased expression of ANAPC5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781
|
|
G |
Anapc7 |
anaphase promoting complex subunit 7 |
increases expression |
ISO |
Coumestrol results in increased expression of ANAPC7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:34,131,214...34,160,819
Ensembl chr12:34,133,429...34,160,005
|
|
G |
Anln |
anillin, actin binding protein |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANLN mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ANLN mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA] Coumestrol results in increased expression of ANLN mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
|
|
G |
Ano6 |
anoctamin 6 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANO6 mRNA Coumestrol results in decreased expression of ANO6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
increases expression |
ISO |
Coumestrol results in increased expression of ANP32A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443
|
|
G |
Anp32e |
acidic nuclear phosphoprotein 32 family member E |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ANP32E mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA] Coumestrol results in increased expression of ANP32E mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 2:183,472,600...183,489,057
Ensembl chr 2:183,472,609...183,489,054
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANXA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa3 |
annexin A3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANXA3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Anxa9 |
annexin A9 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANXA9 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374
|
|
G |
Ap1b1 |
adaptor related protein complex 1 subunit beta 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AP1B1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:79,879,482...79,930,778
Ensembl chr14:79,879,533...79,930,778
|
|
G |
Ap1m1 |
adaptor related protein complex 1 subunit mu 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AP1M1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403
|
|
G |
Ap2s1 |
adaptor related protein complex 2 subunit sigma 1 |
increases expression |
ISO |
Coumestrol results in increased expression of AP2S1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:77,417,496...77,428,903
Ensembl chr 1:77,417,477...77,428,905
|
|
G |
Apbb2 |
amyloid beta precursor protein binding family B member 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of APBB2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:41,557,918...41,878,622
Ensembl chr14:41,557,972...41,877,495
|
|
G |
Apod |
apolipoprotein D |
decreases expression |
ISO |
Coumestrol results in decreased expression of APOD mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
ISO |
Coumestrol results in decreased expression of APP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of AQP3 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AQP3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Ar |
androgen receptor |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of AR mRNA Coumestrol inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein] |
CTD |
PMID:11867264 PMID:29162470 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arfgef2 |
ARF guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ARFGEF2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:155,547,504...155,633,652
Ensembl chr 3:155,547,538...155,630,856
|
|
G |
Arfgef3 |
ARFGEF family member 3 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARFGEF3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ARFGEF3 mRNA Coumestrol results in decreased expression of ARFGEF3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084
|
|
G |
Arhgap19 |
Rho GTPase activating protein 19 |
increases expression |
ISO |
Coumestrol results in increased expression of ARHGAP19 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:240,571,554...240,617,361
Ensembl chr 1:240,580,871...240,617,287
|
|
G |
Arhgap39 |
Rho GTPase activating protein 39 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ARHGAP39 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:108,446,280...108,538,875
Ensembl chr 7:108,446,282...108,538,831
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARHGDIA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARHGEF26 mRNA Coumestrol results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:146,740,336...146,850,918
Ensembl chr 2:146,739,631...146,850,819
|
|
G |
Arhgef37 |
Rho guanine nucleotide exchange factor 37 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARHGEF37 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:54,935,256...55,001,017
Ensembl chr18:54,949,110...55,000,669
|
|
G |
Arhgef39 |
Rho guanine nucleotide exchange factor 39 |
increases expression |
ISO |
Coumestrol results in increased expression of ARHGEF39 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:57,752,509...57,756,079
Ensembl chr 5:57,752,509...57,756,109
|
|
G |
Arid4b |
AT-rich interaction domain 4B |
decreases expression |
ISO |
Coumestrol results in decreased expression of ARID4B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:51,138,419...51,262,894
Ensembl chr17:51,138,535...51,262,906
|
|
G |
Arl3 |
ARF like GTPase 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARL3 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ARL3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820
|
|
G |
Arln |
allregulin |
decreases expression |
ISO |
Coumestrol results in decreased expression of ARLN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:211,055,911...211,057,681
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
decreases expression |
ISO |
Coumestrol results in decreased expression of ARNT mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ARRDC3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Arx |
aristaless related homeobox |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARX mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142
|
|
G |
Asap1 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of ASAP1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ASAP1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ASAP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of ASF1B mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ASF1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ASF1B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Aspm |
assembly factor for spindle microtubules |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ASPM mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ASPM mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA] Coumestrol results in increased expression of ASPM mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATAD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ATAD2 mRNA Coumestrol results in increased expression of ATAD2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
|
|
G |
Atf2 |
activating transcription factor 2 |
increases expression |
ISO |
Coumestrol results in increased expression of ATF2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATF3 mRNA Coumestrol results in decreased expression of ATF3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf5 |
activating transcription factor 5 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATF5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atg14 |
autophagy related 14 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ATG14 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:20,795,750...20,827,113
Ensembl chr15:20,795,750...20,827,113
|
|
G |
Atosa |
atos homolog A |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of ATOSA mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATOSA mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of ATOSA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP1B1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp23 |
ATP23 metallopeptidase and ATP synthase assembly factor homolog |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATP23 mRNA Coumestrol results in increased expression of ATP23 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:62,714,752...62,729,893
Ensembl chr 7:62,714,785...62,729,862
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of ATP2A3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP2B1 mRNA Coumestrol results in decreased expression of ATP2B1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp2c1 |
ATPase secretory pathway Ca2+ transporting 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP2C1 mRNA Coumestrol results in decreased expression of ATP2C1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:106,034,777...106,155,854
Ensembl chr 8:106,034,636...106,156,006
|
|
G |
Atp5mc1 |
ATP synthase membrane subunit c locus 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATP5MC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ATP5MC1 mRNA Coumestrol results in increased expression of ATP5MC1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124 Ensembl chr10:81,023,925...81,027,124
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP6V0E1 mRNA Coumestrol results in decreased expression of ATP6V0E1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of ATP8B2 mRNA Coumestrol results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:175,378,514...175,402,265
Ensembl chr 2:175,378,517...175,401,883
|
|
G |
Atp9a |
ATPase phospholipid transporting 9A (putative) |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of ATP9A mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP9A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818
|
|
G |
Atxn1 |
ataxin 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATXN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
|
|
G |
Aurka |
aurora kinase A |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AURKA mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AURKA mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA] Coumestrol results in increased expression of AURKA mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AURKB mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of AURKB mRNA Coumestrol results in increased expression of AURKB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Auts2 |
activator of transcription and developmental regulator AUTS2 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of AUTS2 mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of AUTS2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:24,104,187...25,194,123
Ensembl chr12:24,104,192...25,194,416
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
Coumestrol results in increased expression of B2M mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
B3galnt1 |
beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of B3GALNT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:153,847,297...153,877,371
Ensembl chr 2:153,846,474...153,877,332
|
|
G |
B3gnt5 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of B3GNT5 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of B3GNT5 mRNA Coumestrol results in decreased expression of B3GNT5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BACE1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bace2 |
beta-secretase 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BACE2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bag2 |
BAG cochaperone 2 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of BAG2 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of BAG2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
|
|
G |
Bag3 |
BAG cochaperone 3 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BAG3 mRNA Coumestrol results in decreased expression of BAG3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bag5 |
BAG cochaperone 5 |
decreases expression |
ISO |
Coumestrol results in decreased expression of BAG5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970
|
|
G |
Banf1 |
barrier to autointegration nuclear assembly factor 1 |
increases expression |
ISO |
Coumestrol results in increased expression of BANF1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BARD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BARD1 mRNA Coumestrol results in increased expression of BARD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression affects binding |
ISO |
Coumestrol results in increased expression of BAX protein Coumestrol binds to BAX protein |
CTD |
PMID:28986287 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Baz2a |
bromodomain adjacent to zinc finger domain, 2A |
decreases expression |
ISO |
Coumestrol results in decreased expression of BAZ2A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:523,204...560,911
Ensembl chr 7:523,265...560,659
|
|
G |
Bbs1 |
Bardet-Biedl syndrome 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of BBS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:202,184,812...202,204,118
Ensembl chr 1:202,186,125...202,204,086
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCAR3 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of BCAR3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Bcas3 |
BCAS3, microtubule associated cell migration factor |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of BCAS3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:70,213,710...70,673,080
Ensembl chr10:70,214,098...70,673,080
|
|
G |
Bckdhb |
branched chain keto acid dehydrogenase E1 subunit beta |
decreases expression |
ISO |
Coumestrol results in decreased expression of BCKDHB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:84,845,264...85,027,812
Ensembl chr 8:84,845,264...85,027,812
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions affects binding |
ISO |
Coumestrol results in decreased expression of BCL2 protein [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2 mRNA Coumestrol binds to BCL2 protein |
CTD |
PMID:19167446 PMID:20623010 PMID:28986287 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l12 |
Bcl2 like 12 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2L12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BCL2L12 mRNA Coumestrol results in increased expression of BCL2L12 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:95,472,272...95,480,991
Ensembl chr 1:95,472,272...95,480,991
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCL3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BCL3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bcl9 |
BCL9, transcription coactivator |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCL9 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435
|
|
G |
Bcl9l |
BCL9 like |
decreases expression |
ISO |
Coumestrol results in decreased expression of BCL9L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:44,811,977...44,840,611
Ensembl chr 8:44,811,977...44,840,611
|
|
G |
Bclaf1 |
BCL2-associated transcription factor 1 |
increases expression |
ISO |
Coumestrol results in increased expression of BCLAF1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832
|
|
G |
Bclaf3 |
BCLAF1 and THRAP3 family member 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of BCLAF3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:35,257,228...35,328,883
Ensembl chr X:35,263,576...35,328,816
|
|
G |
Bcs1l |
BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone |
increases expression |
ISO |
Coumestrol results in increased expression of BCS1L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:76,164,925...76,168,940
Ensembl chr 9:76,164,932...76,168,938
|
|
G |
Bex1 |
brain expressed X-linked 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BEX2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:99,219,014...99,220,518
Ensembl chr X:99,219,014...99,220,958
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BHLHE40 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BHLHE40 mRNA Coumestrol results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of BIK mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bin3 |
bridging integrator 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA] |
CTD |
PMID:18310284 |
|
NCBI chr15:45,173,725...45,212,607
Ensembl chr15:45,173,732...45,212,604
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BIRC5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BIRC5 mRNA Coumestrol results in increased expression of BIRC5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Blm |
BLM RecQ like helicase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BLM mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BLM mRNA Coumestrol results in increased expression of BLM mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312
|
|
G |
Blnk |
B-cell linker |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BLNK mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BLNK mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:239,753,640...239,821,113
Ensembl chr 1:239,753,648...239,821,113
|
|
G |
Bloc1s6 |
biogenesis of lysosomal organelles complex 1 subunit 6 |
decreases expression |
ISO |
Coumestrol results in decreased expression of BLOC1S6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:109,816,397...109,826,528
Ensembl chr 3:109,816,366...109,828,308
|
|
G |
Bltp2 |
bridge-like lipid transfer protein family member 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BLTP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:63,155,999...63,185,213
Ensembl chr10:63,156,044...63,191,141
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
Coumestrol results in increased expression of BLVRB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Blzf1 |
basic leucine zipper nuclear factor 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of BLZF1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:76,641,757...76,656,977
Ensembl chr13:76,641,515...76,656,999
|
|
G |
Bmerb1 |
bMERB domain containing 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMERB1 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of BMERB1 mRNA Coumestrol results in decreased expression of BMERB1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:1,779,834...1,946,586
Ensembl chr10:1,779,835...1,946,575
|
|
G |
Bmf |
Bcl2 modifying factor |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMF mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMF mRNA Coumestrol results in decreased expression of BMF mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
Coumestrol inhibits the reaction [menatetrenone promotes the reaction [Phosphates results in increased expression of BMP2 mRNA]]; Coumestrol inhibits the reaction [menatetrenone results in increased expression of BMP2 mRNA]; Coumestrol inhibits the reaction [menatetrenone results in increased susceptibility to BMP2 protein]; Coumestrol inhibits the reaction [Phosphates promotes the reaction [menatetrenone results in increased expression of BMP2 mRNA]] |
CTD |
PMID:31843813 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of BMP5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMP7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMP7 mRNA Coumestrol results in decreased expression of BMP7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMPR2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BMPR2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
decreases expression |
ISO |
Coumestrol results in decreased expression of BNIP3L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Bora |
bora, aurora kinase A activator |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of BORA mRNA [Coumestrol co-treated with resveratrol] results in increased expression of BORA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
|
|
G |
Brat1 |
BRCA1-associated ATM activator 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRAT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:13,928,889...13,951,760
Ensembl chr12:13,928,898...13,941,248
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BRCA1 mRNA Coumestrol results in increased expression of BRCA1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BRCA2 mRNA Coumestrol results in increased expression of BRCA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Brd3 |
bromodomain containing 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of BRD3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:10,773,163...10,829,675
Ensembl chr 3:10,775,272...10,829,577
|
|
G |
Bri3 |
brain protein I3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of BRI3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:10,341,007...10,364,655
Ensembl chr12:10,341,011...10,364,735
|
|
G |
Bri3bp |
Bri3 binding protein |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRI3BP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:31,176,742...31,188,563
Ensembl chr12:31,173,971...31,188,572
|
|
G |
Brwd1 |
bromodomain and WD repeat domain containing 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BRWD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:35,286,364...35,378,768
Ensembl chr11:35,288,313...35,378,768
|
|
G |
Bsdc1 |
BSD domain containing 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BSDC1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092
|
|
G |
Bsg |
basigin |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BSG mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Btbd7 |
BTB domain containing 7 |
decreases expression |
ISO |
Coumestrol results in decreased expression of BTBD7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:121,920,365...122,010,114
Ensembl chr 6:121,923,023...121,972,405
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BTG1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of BTG1 mRNA Coumestrol results in decreased expression of BTG1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of BTG2 mRNA Coumestrol results in decreased expression of BTG2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of BUB1 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of BUB1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BUB1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of BUB1B mRNA Coumestrol results in increased expression of BUB1B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C11h3orf52 |
similar to human chromosome 3 open reading frame 52 |
decreases expression |
ISO |
Coumestrol results in decreased expression of C3ORF52 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:55,166,986...55,192,273
Ensembl chr11:55,166,678...55,192,292
|
|
G |
C13h1orf115 |
similar to human chromosome 1 open reading frame 115 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of C1ORF115 mRNA Coumestrol results in decreased expression of C1ORF115 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:96,422,308...96,432,044
Ensembl chr13:96,422,302...96,432,068
|
|
G |
C18h18orf32 |
similar to human chromosome 18 open reading frame 32 |
decreases expression |
ISO |
Coumestrol results in decreased expression of C18ORF32 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:68,586,278...68,594,851
Ensembl chr18:68,586,211...68,596,787
|
|
G |
C1h9orf40 |
similar to human chromosome 9 open reading frame 40 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of C9ORF40 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C9ORF40 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of C9ORF40 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:216,128,687...216,132,896
Ensembl chr 1:216,128,651...216,133,045
|
|
G |
C2h4orf46 |
similar to human chromosome 4 open reading frame 46 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of C4ORF46 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of C4ORF46 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:164,762,994...164,766,126
Ensembl chr 2:164,762,960...164,766,128
|
|
G |
C2h5orf34 |
similar to human chromosome 5 open reading frame 34 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of C5ORF34 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C5ORF34 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:51,553,223...51,577,090
Ensembl chr 2:51,555,432...51,577,085
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
C5h9orf152 |
similar to human chromosome 9 open reading frame 152 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of C9ORF152 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of C9ORF152 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:72,660,573...72,667,941
Ensembl chr 5:72,660,573...72,668,379
|
|
G |
C9h2orf69 |
similar to human chromosome 2 open reading frame 69 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of C2ORF69 mRNA Coumestrol results in increased expression of C2ORF69 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:58,949,821...58,958,456
Ensembl chr 9:58,949,846...58,958,561
|
|
G |
Cacybp |
calcyclin binding protein |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CACYBP mRNA [Coumestrol co-treated with resveratrol] results in increased expression of CACYBP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CADM1 mRNA Coumestrol results in decreased expression of CADM1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Calcr |
calcitonin receptor |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CALCR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:31,661,270...31,736,392
Ensembl chr 4:31,661,273...31,736,392
|
|
G |
Calm3 |
calmodulin 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CALM3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207
|
|
G |
Calu |
calumenin |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CALU mRNA Coumestrol results in increased expression of CALU mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Camk1d |
calcium/calmodulin-dependent protein kinase ID |
decreases expression |
ISO |
Coumestrol results in decreased expression of CAMK1D mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:72,581,899...72,982,704
Ensembl chr17:72,581,979...72,980,556
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CAMK2D mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAMK2D mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAMK2N1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CAMK2N1 mRNA Coumestrol results in decreased expression of CAMK2N1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
|
|
G |
Cant1 |
calcium activated nucleotidase 1 |
increases expression |
ISO |
Coumestrol results in increased expression of CANT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:103,637,079...103,650,240
Ensembl chr10:103,531,504...103,650,109
|
|
G |
Car12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CA12 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Carhsp1 |
calcium regulated heat stable protein 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CARHSP1 mRNA Coumestrol results in increased expression of CARHSP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:6,946,036...6,960,556
Ensembl chr10:6,946,959...7,020,019
|
|
G |
Casp3 |
caspase 3 |
increases expression |
EXP ISO |
Coumestrol results in increased expression of CASP3 protein |
CTD |
PMID:19165469 PMID:28986287 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases expression |
EXP |
Coumestrol results in increased expression of CASP7 protein |
CTD |
PMID:19165469 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CASP8AP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Coumestrol results in increased expression of CASP9 protein |
CTD |
PMID:28986287 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAST mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CAV1 mRNA Coumestrol results in increased expression of CAV1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cbfb |
core-binding factor subunit beta |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CBFB mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CBFB mRNA Coumestrol results in increased expression of CBFB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:33,049,162...33,092,752
Ensembl chr19:33,049,172...33,092,751
|
|
G |
Cblb |
Cbl proto-oncogene B |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CBLB mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CBLB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:48,589,878...48,756,940
Ensembl chr11:48,592,703...48,756,839
|
|
G |
Cbr1 |
carbonyl reductase 1 |
increases expression |
ISO |
Coumestrol results in increased expression of CBR1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbx4 |
chromobox 4 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CBX4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706
|
|
G |
Cbx5 |
chromobox 5 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CBX5 mRNA Coumestrol results in increased expression of CBX5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
|
|
G |
Ccdc117 |
coiled-coil domain containing 117 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CCDC117 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:80,399,236...80,409,824
Ensembl chr14:80,400,294...80,409,659
|
|
G |
Ccdc14 |
coiled-coil domain containing 14 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCDC14 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCDC14 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:66,052,063...66,087,915
Ensembl chr11:66,052,620...66,087,956
|
|
G |
Ccdc167 |
coiled-coil domain containing 167 |
increases expression |
ISO |
Coumestrol results in increased expression of CCDC167 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:7,763,927...7,782,090
Ensembl chr20:7,751,782...7,781,613
|
|
G |
Ccdc34 |
coiled-coil domain containing 34 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CCDC34 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCDC34 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:96,553,074...96,588,310
Ensembl chr 3:96,552,992...96,588,146
|
|
G |
Ccdc47 |
coiled-coil domain containing 47 |
increases expression |
ISO |
Coumestrol results in increased expression of CCDC47 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:91,130,303...91,148,829
Ensembl chr10:91,130,303...91,148,881
|
|
G |
Ccdc51 |
coiled-coil domain containing 51 |
increases expression |
ISO |
Coumestrol results in increased expression of CCDC51 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:109,722,595...109,741,478
Ensembl chr 8:109,722,557...109,741,472
|
|
G |
Ccdc88c |
coiled-coil domain containing 88C |
decreases expression |
ISO |
Coumestrol results in decreased expression of CCDC88C mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:120,169,752...120,289,459
Ensembl chr 6:120,169,738...120,289,555
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CCN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn5 |
cellular communication network factor 5 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCN5 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CCN5 mRNA; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CCN5 mRNA] |
CTD |
PMID:19167446 PMID:23384675 |
|
NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression increases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CCNA2 protein Coumestrol results in increased expression of CCNA2 protein [Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA] |
CTD |
PMID:18310284 PMID:20623010 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNB1 mRNA Coumestrol results in increased expression of CCNB1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNB2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNB2 mRNA Coumestrol results in increased expression of CCNB2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
ISO |
CCND1 protein promotes the reaction [Coumestrol results in increased activity of ESR1 protein] Coumestrol results in increased expression of CCND1 mRNA |
CTD |
PMID:16328721 PMID:19800779 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CCNE1 protein |
CTD |
PMID:28986287 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNE2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CCNE2 mRNA Coumestrol results in increased expression of CCNE2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccnf |
cyclin F |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNF mRNA Coumestrol results in increased expression of CCNF mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CCNG2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccni |
cyclin I |
decreases expression |
ISO |
Coumestrol results in decreased expression of CCNI mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:14,879,698...14,902,510
Ensembl chr14:14,879,717...14,902,510
|
|
G |
Ccp110 |
centriolar coiled-coil protein 110 |
multiple interactions |
ISO |
[Coumestrol co-treated with Resveratrol] results in increased expression of CCP110 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:173,042,238...173,072,873
Ensembl chr 1:173,042,310...173,072,873
|
|
G |
Ccpg1 |
cell cycle progression 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CCPG1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CCPG1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of CD24 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd320 |
CD320 molecule |
increases expression |
ISO |
Coumestrol results in increased expression of CD320 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:14,626,171...14,631,976
Ensembl chr 7:14,609,146...14,631,976
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CD44 mRNA Coumestrol results in increased expression of CD44 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CD55 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CD55 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd59b |
CD59b molecule |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CD59 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cdc14b |
cell division cycle 14B |
decreases expression |
ISO |
Coumestrol results in decreased expression of CDC14B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235
|
|
G |
Cdc25a |
cell division cycle 25A |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CDC25A mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC25A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC25A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25c |
cell division cycle 25C |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CDC25C mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC25C mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC25C mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CDC27 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC27 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC27 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736
|
|
G |
Cdc42bpb |
CDC42 binding protein kinase beta |
decreases expression |
ISO |
Coumestrol results in decreased expression of CDC42BPB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:130,333,712...130,416,631
Ensembl chr 6:130,333,712...130,416,377
|
|
G |
Cdc45 |
cell division cycle 45 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CDC45 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC45 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDC45 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdc5l |
cell division cycle 5-like |
increases expression |
ISO |
Coumestrol results in increased expression of CDC5L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:15,564,949...15,603,453
Ensembl chr 9:15,564,767...15,603,450
|
|
G |
Cdc6 |
cell division cycle 6 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC6 mRNA Coumestrol results in increased expression of CDC6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdc7 |
cell division cycle 7 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC7 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDC7 mRNA Coumestrol results in increased expression of CDC7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:2,804,660...2,824,796
Ensembl chr14:2,804,661...2,824,778
|
|
G |
Cdca2 |
cell division cycle associated 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA2 mRNA Coumestrol results in increased expression of CDCA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdca3 |
cell division cycle associated 3 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA3 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA] Coumestrol results in increased expression of CDCA3 mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdca4 |
cell division cycle associated 4 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:131,892,305...131,901,571
Ensembl chr 6:131,892,087...131,901,564
|
|
G |
Cdca5 |
cell division cycle associated 5 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA5 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDCA5 mRNA Coumestrol results in increased expression of CDCA5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA7L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA7L mRNA Coumestrol results in increased expression of CDCA7L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888
|
|
G |
Cdca8 |
cell division cycle associated 8 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDCA8 mRNA Coumestrol results in increased expression of CDCA8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh12 |
cadherin 12 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDH12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDH12 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:70,474,679...71,705,369
Ensembl chr 2:70,475,043...71,700,572
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CDK1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CDK1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk13 |
cyclin-dependent kinase 13 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CDK13 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:47,251,145...47,344,675
Ensembl chr17:47,251,163...47,341,721
|
|
G |
Cdk17 |
cyclin-dependent kinase 17 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PCTK2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:27,683,890...27,765,814
Ensembl chr 7:27,683,890...27,764,910
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CDK2 protein |
CTD |
PMID:28986287 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk2ap2 |
cyclin-dependent kinase 2 associated protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK2AP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:201,391,056...201,393,137
Ensembl chr 1:201,391,466...201,393,137
|
|
G |
Cdk5rap2 |
CDK5 regulatory subunit associated protein 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK5RAP2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDK5RAP2 mRNA Coumestrol results in increased expression of CDK5RAP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:83,792,282...83,961,129
Ensembl chr 5:83,792,284...83,960,782
|
|
G |
Cdkl5 |
cyclin-dependent kinase-like 5 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of CDKL5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:33,757,605...33,988,075
Ensembl chr X:33,821,257...33,986,582
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CDKN1A mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
ISO |
Coumestrol results in decreased expression of CDKN1C mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2aip |
CDKN2A interacting protein |
decreases expression |
ISO |
Coumestrol results in decreased expression of CDKN2AIP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:44,536,147...44,546,216
Ensembl chr16:44,536,234...44,540,033
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN2B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CDKN2B mRNA Coumestrol results in decreased expression of CDKN2B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDKN2C mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA] Coumestrol results in increased expression of CDKN2C mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDKN3 mRNA; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA] Coumestrol results in increased expression of CDKN3 mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CDS1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CDT1 mRNA Coumestrol results in increased expression of CDT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cdv3 |
carnitine deficiency-associated gene expressed in ventricle 3 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CDV3 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of CDV3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:103,934,006...103,947,173
Ensembl chr 8:103,933,996...103,947,192
|
|
G |
Cdyl |
chromodomain Y-like |
decreases expression |
ISO |
Coumestrol results in decreased expression of CDYL mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:28,982,009...29,204,345
Ensembl chr17:28,982,037...29,204,313
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CEBPD mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Celsr2 |
cadherin, EGF LAG seven-pass G-type receptor 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CELSR2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CELSR2 mRNA Coumestrol results in increased expression of CELSR2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845
|
|
G |
Cenpa |
centromere protein A |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPA mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CENPA mRNA Coumestrol results in increased expression of CENPA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpe |
centromere protein E |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CENPE mRNA [Coumestrol co-treated with resveratrol] results in increased expression of CENPE mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669
|
|
G |
Cenpf |
centromere protein F |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPF mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPF mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA] Coumestrol results in increased expression of CENPF mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cenph |
centromere protein H |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CENPH mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPH mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:31,896,675...31,910,179
Ensembl chr 2:31,894,667...31,910,154
|
|
G |
Cenpi |
centromere protein I |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CENPI mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPI mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:97,515,919...97,567,671
Ensembl chr X:97,515,972...97,567,657
|
|
G |
Cenpj |
centromere protein J |
increases expression |
ISO |
Coumestrol results in increased expression of CPAP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:30,627,206...30,690,384
Ensembl chr15:30,627,224...30,686,791
|
|
G |
Cenpl |
centromere protein L |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CENPL mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPL mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:73,337,235...73,352,115
Ensembl chr13:73,337,257...73,352,114
|
|
G |
Cenpm |
centromere protein M |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CENPM mRNA Coumestrol results in increased expression of CENPM mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258
|
|
G |
Cenpn |
centromere protein N |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPN mRNA Coumestrol results in increased expression of CENPN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012
|
|
G |
Cenpo |
centromere protein O |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPO mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPO mRNA Coumestrol results in increased expression of CENPO mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314
|
|
G |
Cenpq |
centromere protein Q |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPQ mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPQ mRNA Coumestrol results in increased expression of CENPQ mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:19,957,122...19,972,807
Ensembl chr 9:19,957,048...19,972,789
|
|
G |
Cenps |
centromere protein S |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPS mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of CENPS mRNA Coumestrol results in increased expression of CENPS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:159,563,917...159,573,534
|
|
G |
Cenpu |
centromere protein U |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPU mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPU mRNA Coumestrol results in increased expression of CENPU mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823
|
|
G |
Cenpw |
centromere protein W |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPW mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CENPW mRNA Coumestrol results in increased expression of CENPW mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464
|
|
G |
Cep128 |
centrosomal protein 128 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CEP128 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:109,951,009...110,328,686
Ensembl chr 6:109,951,061...110,328,713
|
|
G |
Cep15 |
centrosomal protein 15 |
increases expression |
ISO |
Coumestrol results in increased expression of CEP15 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838
|
|
G |
Cep152 |
centrosomal protein 152 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CEP152 mRNA Coumestrol results in increased expression of CEP152 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:112,803,185...112,878,298
Ensembl chr 3:112,810,425...112,878,458 Ensembl chr 3:112,810,425...112,878,458
|
|
G |
Cep192 |
centrosomal protein 192 |
increases expression |
ISO |
Coumestrol results in increased expression of CEP192 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:61,373,937...61,458,405
Ensembl chr18:61,332,158...61,458,379
|
|
G |
Cep55 |
centrosomal protein 55 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CEP55 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP55 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CEP55 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394
|
|
G |
Cep57 |
centrosomal protein 57 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CEP57 mRNA Coumestrol results in increased expression of CEP57 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:10,669,588...10,689,257
Ensembl chr 8:10,669,590...10,689,249
|
|
G |
Cep57l1 |
centrosomal protein 57-like 1 |
increases expression |
ISO |
Coumestrol results in increased expression of CEP57L1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:45,238,039...45,294,575
Ensembl chr20:45,238,044...45,294,540
|
|
G |
Cep78 |
centrosomal protein 78 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP78 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CEP78 mRNA Coumestrol results in increased expression of CEP78 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:213,246,183...213,275,275
Ensembl chr 1:213,246,187...213,275,181
|
|
G |
Cep85 |
centrosomal protein 85 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP85 mRNA Coumestrol results in increased expression of CEP85 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:146,356,571...146,404,155
Ensembl chr 5:146,356,576...146,404,060
|
|
G |
Cfap20 |
cilia and flagella associated protein 20 |
increases expression |
ISO |
Coumestrol results in increased expression of CFAP20 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:9,608,867...9,622,558
Ensembl chr19:9,608,859...9,622,558
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
Coumestrol results in decreased expression of CFLAR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cgn |
cingulin |
decreases expression |
ISO |
Coumestrol results in decreased expression of CGN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:182,308,389...182,335,747
Ensembl chr 2:182,308,714...182,334,645
|
|
G |
Chac2 |
ChaC glutathione specific gamma-glutamylcyclotransferase 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAC2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHAC2 mRNA Coumestrol results in increased expression of CHAC2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:104,720,754...104,728,305
Ensembl chr14:104,720,758...104,728,301
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAF1A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHAF1A mRNA Coumestrol results in increased expression of CHAF1A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAF1B mRNA Coumestrol results in increased expression of CHAF1B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CHD2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
|
|
G |
Chd6 |
chromodomain helicase DNA binding protein 6 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CHD6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:149,596,509...149,757,765
Ensembl chr 3:149,596,509...149,757,755
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHEK1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHEK1 mRNA Coumestrol results in increased expression of CHEK1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHEK2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CHEK2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chn1 |
chimerin 1 |
increases expression |
ISO |
Coumestrol results in increased expression of CHN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Chpt1 |
choline phosphotransferase 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHPT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103
|
|
G |
Chrna5 |
cholinergic receptor nicotinic alpha 5 subunit |
increases expression |
ISO |
Coumestrol results in increased expression of CHRNA5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:55,369,794...55,398,526
Ensembl chr 8:55,369,794...55,398,146
|
|
G |
Cip2a |
cellular inhibitor of PP2A |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CIP2A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:51,792,143...51,823,016
Ensembl chr11:51,795,024...51,822,938
|
|
G |
Cisd1 |
CDGSH iron sulfur domain 1 |
increases expression |
ISO |
Coumestrol results in increased expression of CISD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:17,255,302...17,268,688
Ensembl chr20:17,255,151...17,284,924
|
|
G |
Cit |
citron rho-interacting serine/threonine kinase |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CIT mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:40,603,073...40,764,846
Ensembl chr12:40,605,563...40,763,860
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CITED2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CKAP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Ckap2l |
cytoskeleton associated protein 2-like |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of CKAP2L mRNA Coumestrol results in increased expression of CKAP2L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:116,497,186...116,524,302
Ensembl chr 3:116,498,022...116,524,366
|
|
G |
Ckap4 |
cytoskeleton-associated protein 4 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CKAP4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914
|
|
G |
Ckap5 |
cytoskeleton associated protein 5 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CKAP5 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKAP5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:77,491,195...77,593,300
Ensembl chr 3:77,491,276...77,593,264
|
|
G |
Cklf |
chemokine-like factor |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CKLF mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKLF mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:698,097...706,570
Ensembl chr19:698,033...706,570
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKS1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CKS1B mRNA Coumestrol results in increased expression of CKS1B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CKS2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CKS2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Clcc1 |
chloride channel CLIC-like 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA] |
CTD |
PMID:18310284 |
|
NCBI chr 2:196,296,350...196,326,914
Ensembl chr 2:196,296,393...196,326,913
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLDN1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CLDN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLDN4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Clip1 |
CAP-GLY domain containing linker protein 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLIP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:32,910,932...33,017,891
Ensembl chr12:32,910,977...33,017,884
|
|
G |
Cln6 |
CLN6, transmembrane ER protein |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CLN6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360
|
|
G |
Cln8 |
CLN8, transmembrane ER and ERGIC protein |
decreases expression |
ISO |
Coumestrol results in decreased expression of CLN8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:74,749,662...74,759,553
Ensembl chr16:74,749,662...74,759,774
|
|
G |
Cltrn |
collectrin, amino acid transport regulator |
decreases expression |
ISO |
Coumestrol results in decreased expression of CLTRN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:30,361,967...30,395,264
Ensembl chr X:30,361,967...30,395,349
|
|
G |
Clu |
clusterin |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLU mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cmc2 |
C-x(9)-C motif containing 2 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CMC2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CMC2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CMC2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:44,943,283...44,971,930
Ensembl chr19:44,943,285...44,971,983
|
|
G |
Cmss1 |
cms1 ribosomal small subunit homolog |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CMSS1 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of CMSS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:42,934,390...43,232,624
Ensembl chr11:42,934,440...43,232,624
|
|
G |
Cmtm8 |
CKLF-like MARVEL transmembrane domain containing 8 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CMTM8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:114,481,730...114,547,107
Ensembl chr 8:114,481,982...114,547,083
|
|
G |
Cobl |
cordon-bleu WH2 repeat protein |
decreases expression |
ISO |
Coumestrol results in decreased expression of COBL mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800
|
|
G |
Coch |
cochlin |
increases expression |
ISO |
Coumestrol results in increased expression of COCH mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109
|
|
G |
Cog4 |
component of oligomeric golgi complex 4 |
increases expression |
ISO |
Coumestrol results in increased expression of COG4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:38,820,478...38,854,803
Ensembl chr19:38,820,501...38,854,796
|
|
G |
Cog5 |
component of oligomeric golgi complex 5 |
decreases expression |
ISO |
Coumestrol results in decreased expression of COG5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:48,242,470...48,545,185
Ensembl chr 6:48,242,482...48,529,009
|
|
G |
Cog6 |
component of oligomeric golgi complex 6 |
decreases expression |
ISO |
Coumestrol results in decreased expression of COG6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:137,062,127...137,099,176
Ensembl chr 2:137,061,346...137,099,190
|
|
G |
Commd4 |
COMM domain containing 4 |
increases expression |
ISO |
Coumestrol results in increased expression of COMMD4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:57,566,236...57,569,701
Ensembl chr 8:57,566,236...57,569,760
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of COMT mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of COMT mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cops2 |
COP9 signalosome subunit 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of COPS2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:113,084,174...113,110,090
Ensembl chr 3:113,084,176...113,109,947
|
|
G |
Coq2 |
coenzyme Q2, polyprenyltransferase |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of COQ2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:8,941,429...8,961,418
Ensembl chr14:8,941,461...8,960,891
|
|
G |
Coq7 |
coenzyme Q7, hydroxylase |
increases expression |
ISO |
Coumestrol results in increased expression of COQ7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:172,836,359...172,851,173
Ensembl chr 1:172,835,188...172,851,158
|
|
G |
Coro1b |
coronin 1B |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CORO1B mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of CORO1B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:201,442,977...201,448,416
Ensembl chr 1:201,443,014...201,448,416
|
|
G |
Coro1c |
coronin 1C |
increases expression |
ISO |
Coumestrol results in increased expression of CORO1C mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179
|
|
G |
Coro2a |
coronin 2A |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CORO2A mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of CORO2A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035
|
|
G |
Cpe |
carboxypeptidase E |
decreases expression |
ISO |
Coumestrol results in decreased expression of CPE mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cpeb2 |
cytoplasmic polyadenylation element binding protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of CPEB2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:67,787,503...67,839,973
Ensembl chr14:67,787,507...67,840,743
|
|
G |
Cpsf3 |
cleavage and polyadenylation specific factor 3 |
increases expression |
ISO |
Coumestrol results in increased expression of CPSF3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:40,836,121...40,864,129
Ensembl chr 6:40,836,097...40,864,128
|
|
G |
Cracd |
capping protein inhibiting regulator of actin dynamics |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CRACD mRNA Coumestrol results in decreased expression of CRACD mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:31,284,066...31,520,103
Ensembl chr14:31,284,184...31,522,431
|
|
G |
Creb3l4 |
cAMP responsive element binding protein 3-like 4 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of CREB3L4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:175,690,340...175,695,846
Ensembl chr 2:175,690,335...175,695,932
|
|
G |
Crip2 |
cysteine-rich protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of CRIP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CRY1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CRY1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Cse1l |
chromosome segregation 1 like |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CSE1L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CSE1L mRNA Coumestrol results in increased expression of CSE1L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865
|
|
G |
Csnk1a1 |
casein kinase 1, alpha 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CSNK1A1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271
|
|
G |
Csnk1g1 |
casein kinase 1, gamma 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CSNK1G1 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of CSNK1G1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:66,439,760...66,577,247
Ensembl chr 8:66,439,864...66,572,826
|
|
G |
Csnk1g3 |
casein kinase 1, gamma 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CSNK1G3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:47,299,547...47,386,538
Ensembl chr18:47,299,579...47,386,535
|
|
G |
Csnk2a2 |
casein kinase 2 alpha 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CSNK2A2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:9,556,443...9,596,080
Ensembl chr19:9,556,260...9,596,080
|
|
G |
Cspg5 |
chondroitin sulfate proteoglycan 5 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CSPG5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AXUD1 mRNA Coumestrol results in decreased expression of AXUD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Csrnp2 |
cysteine and serine rich nuclear protein 2 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CSRNP2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CSRNP2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CSRNP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:131,594,232...131,610,075
Ensembl chr 7:131,594,232...131,610,075
|
|
G |
Csta |
cystatin A |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CSTA mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of CSTA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:64,620,483...64,631,488
Ensembl chr11:64,620,483...64,631,488
|
|
G |
Cstf1 |
cleavage stimulation factor subunit 1 |
increases expression |
ISO |
Coumestrol results in increased expression of CSTF1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:161,144,522...161,156,294
Ensembl chr 3:161,144,548...161,156,300
|
|
G |
Cstf2 |
cleavage stimulation factor subunit 2 |
increases expression |
ISO |
Coumestrol results in increased expression of CSTF2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:97,253,559...97,279,476
Ensembl chr X:97,253,586...97,279,476
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CTBP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Ctdspl2 |
CTD small phosphatase like 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTDSPL2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTDSPL2 mRNA Coumestrol results in increased expression of CTDSPL2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:108,915,263...108,970,620
Ensembl chr 3:108,915,280...108,967,227
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTNNAL1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA] Coumestrol results in increased expression of CTNNAL1 mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431
|
|
G |
Ctnnd1 |
catenin delta 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CTNND1 mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of CTNND1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516
|
|
G |
Ctnnd2 |
catenin delta 2 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CTNND2 mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of CTNND2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:81,168,525...82,016,495
Ensembl chr 2:81,167,117...82,015,764
|
|
G |
Ctps1 |
CTP synthase 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CTPS1 mRNA [Coumestrol co-treated with Resveratrol] results in increased expression of CTPS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctr9 |
CTR9 homolog, Paf1/RNA polymerase II complex component |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTR9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CTR9 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:165,137,277...165,167,303
Ensembl chr 1:165,137,215...165,167,303
|
|
G |
Ctsb |
cathepsin B |
decreases expression |
ISO |
Coumestrol results in decreased expression of CTSB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsc |
cathepsin C |
increases expression |
ISO |
Coumestrol results in increased expression of CTSC mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
|
|
G |
Ctsh |
cathepsin H |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of CTSH mRNA Coumestrol results in decreased expression of CTSH mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824
|
|
G |
Cttn |
cortactin |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CTTN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cttnbp2nl |
CTTNBP2 N-terminal like |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CTTNBP2NL mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of CTTNBP2NL mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:192,507,963...192,554,548
Ensembl chr 2:192,507,963...192,541,101
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of CXCL12 mRNA; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA] |
CTD |
PMID:18310284 PMID:19167446 PMID:23384675 PMID:28396216 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxxc5 |
CXXC finger protein 5 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CXXC5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:27,427,591...27,458,579
Ensembl chr18:27,427,230...27,458,673
|
|
G |
Cyb5b |
cytochrome b5 type B |
increases expression |
ISO |
Coumestrol results in increased expression of CYB5B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CYB5R1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of CYB5R1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CYFIP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of CYP1B1 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of CYP1B1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2r1 |
cytochrome P450, family 2, subfamily r, polypeptide 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CYP2R1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Coumestrol results in increased expression of CYP51A1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Cyren |
cell cycle regulator of NHEJ |
increases expression |
ISO |
Coumestrol results in increased expression of CYREN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:63,547,311...63,553,394
Ensembl chr 4:63,547,335...63,551,602
|
|
G |
Cyrib |
CYFIP related Rac1 interactor B |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of CYRIB mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CYRIB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:95,633,876...95,760,588
Ensembl chr 7:95,633,876...95,697,686
|
|
G |
Cyth2 |
cytohesin 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of CYTH2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:96,283,182...96,291,094
Ensembl chr 1:96,284,252...96,291,092
|
|
G |
Daam1 |
dishevelled associated activator of morphogenesis 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of DAAM1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:90,389,544...90,550,114
Ensembl chr 6:90,389,688...90,550,114
|
|
G |
Dancr |
differentiation antagonizing non-protein coding RNA |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DANCR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:34,126,956...34,127,936
|
|
G |
Dars2 |
aspartyl-tRNA synthetase 2 (mitochondrial) |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of DARS2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DARS2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:73,308,726...73,336,558
Ensembl chr13:73,308,726...73,336,934
|
|
G |
Dbf4 |
DBF4-CDC7 kinase regulatory subunit |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DBF4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DBF4 mRNA Coumestrol results in increased expression of DBF4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dbn1 |
drebrin 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DBN1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DBN1 mRNA Coumestrol results in decreased expression of DBN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dcaf15 |
DDB1 and CUL4 associated factor 15 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCAF15 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:24,053,925...24,061,277
Ensembl chr19:24,053,925...24,061,277
|
|
G |
Dcaf4 |
DDB1 and CUL4 associated factor 4 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCAF4 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DCAF4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982
|
|
G |
Dcaf5 |
DDB1 and CUL4 associated factor 5 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DCAF5 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCAF5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110
|
|
G |
Dck |
deoxycytidine kinase |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of DCK mRNA [Coumestrol co-treated with resveratrol] results in increased expression of DCK mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DCLK1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCLK1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DCLK1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Dclre1a |
DNA cross-link repair 1A |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of DCLRE1A mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCLRE1A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DCLRE1A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:255,569,911...255,589,815
Ensembl chr 1:255,569,919...255,589,678
|
|
G |
Dclre1b |
DNA cross-link repair 1B |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCLRE1B mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DCLRE1B mRNA Coumestrol results in increased expression of DCLRE1B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423
|
|
G |
Dcps |
decapping enzyme, scavenger |
increases expression |
ISO |
Coumestrol results in increased expression of DCPS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389
|
|
G |
Dctpp1 |
dCTP pyrophosphatase 1 |
increases expression |
ISO |
Coumestrol results in increased expression of DCTPP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:181,877,440...181,880,833
Ensembl chr 1:181,877,437...181,880,839
|
|
G |
Ddah2 |
DDAH family member 2, ADMA-independent |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DDAH2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DDAH2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DDAH2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:3,761,460...3,764,718
Ensembl chr20:3,761,465...3,764,511
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of DDB2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDB2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DDB2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
|
|
G |
Ddias |
DNA damage-induced apoptosis suppressor |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDIAS mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DDIAS mRNA Coumestrol results in increased expression of DDIAS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DDIT4 mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of DDIT4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddx11 |
DEAD/H-box helicase 11 |
increases expression |
ISO |
Coumestrol results in increased expression of DDX11 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550
|
|
G |
Ddx39a |
DExD-box helicase 39A |
increases expression |
ISO |
Coumestrol results in increased expression of DDX39A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954
|
|
G |
Ddx39b |
DExD-box helicase 39B |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDX39B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996
|
|
G |
Ddx56 |
DEAD-box helicase 56 |
increases expression |
ISO |
Coumestrol results in increased expression of DDX56 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:81,112,008...81,122,331
Ensembl chr14:81,112,012...81,122,333
|
|
G |
Dek |
DEK proto-oncogene |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of DEK mRNA [Coumestrol co-treated with resveratrol] results in increased expression of DEK mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Dennd11 |
DENN domain containing 11 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DENND11 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DENND11 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:69,197,161...69,266,013
Ensembl chr 4:69,198,068...69,228,821
|
|
G |
Dennd1a |
DENN domain containing 1A |
increases expression |
ISO |
Coumestrol results in increased expression of DENND1A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062
|
|
G |
Dennd1b |
DENN domain containing 1B |
decreases expression |
ISO |
Coumestrol results in decreased expression of DENND1B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:50,545,324...50,772,922
Ensembl chr13:50,545,836...50,770,601
|
|
G |
Dennd1c |
DENN domain containing 1C |
decreases expression |
ISO |
Coumestrol results in decreased expression of DENND1C mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:1,904,040...1,916,329
Ensembl chr 9:1,904,045...1,916,187
|
|
G |
Denr |
density regulated reinitiation and release factor |
increases expression |
ISO |
Coumestrol results in increased expression of DENR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:32,662,512...32,685,283
Ensembl chr12:32,662,516...32,683,843
|
|
G |
Depdc1 |
DEP domain containing 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DEPDC1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA] Coumestrol results in increased expression of DEPDC1 mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 2:248,684,508...248,717,951
Ensembl chr 2:248,684,523...248,717,951
|
|
G |
Depdc1b |
DEP domain containing 1B |
multiple interactions |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA] |
CTD |
PMID:18310284 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DEPTOR mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DEPTOR mRNA Coumestrol results in increased expression of DEPTOR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Dera |
deoxyribose-phosphate aldolase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DERA mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DERA mRNA Coumestrol results in increased expression of DERA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:170,663,689...170,742,469
Ensembl chr 4:170,663,665...170,758,865
|
|
G |
Desi2 |
desumoylating isopeptidase 2 |
increases expression |
ISO |
Coumestrol results in increased expression of DESI2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:89,961,767...90,011,255
Ensembl chr13:89,961,934...90,016,416
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of DHCR7 mRNA Coumestrol results in increased expression of DHCR7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhfr |
dihydrofolate reductase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHFR mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DHFR mRNA Coumestrol results in increased expression of DHFR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Dhrs2 |
dehydrogenase/reductase 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DHRS2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA] Coumestrol results in increased expression of DHRS2 mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644
|
|
G |
Dhrs7 |
dehydrogenase/reductase 7 |
decreases expression |
ISO |
Coumestrol results in decreased expression of DHRS7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892
|
|
G |
Dhtkd1 |
dehydrogenase E1 and transketolase domain containing 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHTKD1 mRNA Coumestrol results in increased expression of DHTKD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:72,355,201...72,406,725
Ensembl chr17:72,355,201...72,406,723
|
|
G |
Diaph3 |
diaphanous-related formin 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DIAPH3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DIAPH3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:62,543,375...63,013,060
Ensembl chr15:62,543,375...63,012,975
|
|
G |
Dicer1 |
dicer 1 ribonuclease III |
decreases expression |
ISO |
Coumestrol results in decreased expression of DICER1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
|
|
G |
Dip2c |
disco-interacting protein 2 homolog C |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DIP2C mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:60,647,346...61,032,467
Ensembl chr17:60,649,065...61,032,305
|
|
G |
Dixdc1 |
DIX domain containing 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of DIXDC1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:51,007,835...51,081,191
Ensembl chr 8:51,007,838...51,081,090
|
|
G |
Dkc1 |
dyskerin pseudouridine synthase 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DKC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DKC1 mRNA Coumestrol results in increased expression of DKC1 mRNA |
CTD |
PMID:19167446 |
|
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
increases expression |
ISO |
Coumestrol results in increased expression of DLAT mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479 Ensembl chr 1:50,978,051...51,004,479
|
|
G |
Dlgap5 |
DLG associated protein 5 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of DLGAP5 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DLGAP5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DLGAP5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dlx2 |
distal-less homeobox 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DLX2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597
|
|
G |
Dmac2l |
distal membrane arm assembly component 2 like |
decreases expression |
ISO |
Coumestrol results in decreased expression of DMAC2L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:88,205,580...88,223,934
Ensembl chr 6:88,205,700...88,223,933
|
|
G |
Dmxl1 |
Dmx-like 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DMXL1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456
|
|
G |
Dnaja2 |
DnaJ heat shock protein family (Hsp40) member A2 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DNAJA2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNAJA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DNAJB9 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc1 |
DnaJ heat shock protein family (Hsp40) member C1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of DNAJC1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988
|
|
G |
Dnajc16 |
DnaJ heat shock protein family (Hsp40) member C16 |
decreases expression |
ISO |
Coumestrol results in decreased expression of DNAJC16 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136
|
|
G |
Dnajc9 |
DnaJ heat shock protein family (Hsp40) member C9 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNAJC9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DNAJC9 mRNA Coumestrol results in increased expression of DNAJC9 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118
|
|
G |
Dnase2 |
deoxyribonuclease 2, lysosomal |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNASE2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:23,244,656...23,247,376
Ensembl chr19:23,244,664...23,247,376
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNM1L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNMT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DNMT1 mRNA Coumestrol results in increased expression of DNMT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dock8 |
dedicator of cytokinesis 8 |
decreases expression |
ISO |
Coumestrol results in decreased expression of DOCK8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:222,649,309...222,842,474
Ensembl chr 1:222,649,309...222,842,474
|
|
G |
Donson |
DNA replication fork stabilization factor DONSON |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of DONSON mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DONSON mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DONSON mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889
|
|
G |
Dop1b |
DOP1 leucine zipper like protein B |
decreases expression |
ISO |
Coumestrol results in decreased expression of DOP1B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:33,024,376...33,125,931
Ensembl chr11:33,024,411...33,125,931
|
|
G |
Dpagt1 |
dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 |
increases expression |
ISO |
Coumestrol results in increased expression of DPAGT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:44,664,055...44,671,102
Ensembl chr 8:44,664,071...44,671,087
|
|
G |
Dpm2 |
dolichyl-phosphate mannosyltransferase subunit 2, regulatory |
increases expression |
ISO |
Coumestrol results in increased expression of DPM2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:15,855,952...15,858,867
Ensembl chr 3:15,856,182...15,869,165 Ensembl chr 3:15,856,182...15,869,165
|
|
G |
Dpy19l1 |
dpy-19 like C-mannosyltransferase 1 |
increases expression |
ISO |
Coumestrol results in increased expression of DPY19L1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:22,933,163...23,021,461
Ensembl chr 8:22,933,163...23,021,751
|
|
G |
Dsc2 |
desmocollin 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of DSC2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DSCC1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DSCC1 mRNA Coumestrol results in increased expression of DSCC1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Dsn1 |
DSN1 component of MIS12 kinetochore complex |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DSN1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of DSN1 mRNA Coumestrol results in increased expression of DSN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:145,652,741...145,668,025
Ensembl chr 3:145,652,737...145,665,856
|
|
G |
Dtna |
dystrobrevin, alpha |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DTNA mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DTNA mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DTNA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:14,687,193...14,944,232
Ensembl chr18:14,587,852...14,944,261
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DUSP1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of DUSP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DUSP10 mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of DUSP10 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp22 |
dual specificity phosphatase 22 |
decreases expression |
ISO |
Coumestrol results in decreased expression of DUSP22 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:33,780,980...33,831,241
Ensembl chr17:33,780,981...33,831,321
|
|
G |
Dut |
deoxyuridine triphosphatase |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of DUT mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DUT mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of DUT mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771
|
|
G |
Dync1li1 |
dynein cytoplasmic 1 light intermediate chain 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of DYNC1LI1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DYNC1LI1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934
|
|
G |
Dync2i2 |
dynein 2 intermediate chain 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DYNC2I2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:13,306,039...13,322,121
Ensembl chr 3:13,306,039...13,322,121
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of DYNLT3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of E2F1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of E2F2 mRNA Coumestrol results in increased expression of E2F2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
E2f5 |
E2F transcription factor 5 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of E2F5 mRNA Coumestrol results in decreased expression of E2F5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:86,997,331...87,012,908
Ensembl chr 2:86,997,332...87,012,990
|
|
G |
E2f7 |
E2F transcription factor 7 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of E2F7 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F7 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of E2F7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of E2F8 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F8 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of E2F8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of EBP mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EBP mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EBP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ect2 |
epithelial cell transforming 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ECT2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ECT2 mRNA Coumestrol results in increased expression of ECT2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Edem3 |
ER degradation enhancing alpha-mannosidase like protein 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of EDEM3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:63,858,282...63,920,538
Ensembl chr13:63,858,716...63,920,523
|
|
G |
Edil3 |
EGF like repeats and discoidin domains 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EDIL3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:19,890,396...20,405,028
Ensembl chr 2:19,890,373...20,405,008
|
|
G |
Edn1 |
endothelin 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of EDN1 mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of EDN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eed |
embryonic ectoderm development |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of EED mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EED mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EED mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:143,867,875...143,895,008
Ensembl chr 1:143,867,875...143,894,974
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFEMP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFHD1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFHD1 mRNA Coumestrol results in decreased expression of EFHD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFNA1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFNA1 mRNA Coumestrol results in decreased expression of EFNA1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Efnb2 |
ephrin B2 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFNB2 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EFNB2 mRNA Coumestrol results in decreased expression of EFNB2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391
|
|
G |
Efnb3 |
ephrin B3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of EFNB3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:54,274,506...54,281,951
Ensembl chr10:54,274,506...54,280,471
|
|
G |
Eftud2 |
elongation factor Tu GTP binding domain containing 2 |
increases expression |
ISO |
Coumestrol results in increased expression of EFTUD2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:87,804,893...87,852,181
Ensembl chr10:87,804,892...87,846,079
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EGR1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr3 |
early growth response 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EGR3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EGR3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Ehmt1 |
euchromatic histone lysine methyltransferase 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of EHMT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:7,580,680...7,729,046
Ensembl chr 3:7,580,683...7,729,007
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of EIF2AK3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases expression |
ISO |
Coumestrol results in increased expression of EIF2S1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4ebp2 |
eukaryotic translation initiation factor 4E binding protein 2 |
increases expression |
ISO |
Coumestrol results in increased expression of EIF4EBP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:29,379,444...29,400,110
Ensembl chr20:29,382,668...29,399,946
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of EIF4G3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363
|
|
G |
Elapor1 |
endosome-lysosome associated apoptosis and autophagy regulator 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with Resveratrol] results in decreased expression of ELAPOR1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:196,089,199...196,169,055
Ensembl chr 2:196,091,646...196,168,716
|
|
G |
Elf5 |
E74 like ETS transcription factor 5 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ELF5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELK1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Elk3 |
ETS transcription factor ELK3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ELK3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084
|
|
G |
Elmo2 |
engulfment and cell motility 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ELMO2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185
|
|
G |
Elovl2 |
ELOVL fatty acid elongase 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ELOVL2 mRNA Coumestrol results in increased expression of ELOVL2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848
|
|
G |
Elovl5 |
ELOVL fatty acid elongase 5 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of ELOVL5 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of ELOVL5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:78,790,846...78,857,307
Ensembl chr 8:78,790,846...78,857,284
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL6 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ELOVL6 mRNA Coumestrol results in increased expression of ELOVL6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Elovl7 |
ELOVL fatty acid elongase 7 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL7 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of ELOVL7 mRNA Coumestrol results in increased expression of ELOVL7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:39,789,229...39,858,579
Ensembl chr 2:39,789,250...39,856,845
|
|
G |
Elp5 |
elongator acetyltransferase complex subunit 5 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of ELP5 mRNA Coumestrol results in increased expression of ELP5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923
|
|
G |
Elp6 |
elongator acetyltransferase complex subunit 6 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELP6 mRNA Coumestrol results in increased expression of ELP6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:110,280,059...110,295,070
Ensembl chr 8:110,279,979...110,295,067
|
|
G |
Emc9 |
ER membrane protein complex subunit 9 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EMC9 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EMC9 mRNA Coumestrol results in increased expression of EMC9 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098
|
|
G |
Emd |
emerin |
increases expression |
ISO |
Coumestrol results in increased expression of EMD mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:152,038,990...152,042,190
Ensembl chr X:152,038,998...152,045,807
|
|
G |
Eme1 |
essential meiotic structure-specific endonuclease 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EME1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of ENC1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ENC1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ENC1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Endod1 |
endonuclease domain containing 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of ENDOD1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ENDOD1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ENDOD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:11,209,113...11,238,507
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Enosf1 |
enolase superfamily member 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ENOSF1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:113,275,267...113,314,842
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ENTPD2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866
|
|
G |
Entpd4 |
ectonucleoside triphosphate diphosphohydrolase 4 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ENTPD4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:44,630,878...44,658,654
Ensembl chr15:44,630,873...44,658,706
|
|
G |
Entrep1 |
endosomal transmembrane epsin interactor 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ENTREP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:221,592,500...221,646,603
Ensembl chr 1:221,592,503...221,646,758
|
|
G |
Epb41l2 |
erythrocyte membrane protein band 4.1-like 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of EPB41L2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:19,863,010...20,037,795
Ensembl chr 1:19,863,009...20,037,721
|
|
G |
Epb41l5 |
erythrocyte membrane protein band 4.1 like 5 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EPB41L5 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of EPB41L5 mRNA Coumestrol results in decreased expression of EPB41L5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360
|
|
G |
Epha4 |
Eph receptor A4 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EPHA4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139
|
|
G |
Eps15l1 |
epidermal growth factor receptor pathway substrate 15-like 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EPS15L1 mRNA Coumestrol results in increased expression of EPS15L1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:17,426,345...17,501,677
Ensembl chr16:17,426,421...17,501,677
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ERBB3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ercc6l |
ERCC excision repair 6 like, spindle assembly checkpoint helicase |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of ERCC6L mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ERCC6L mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ERCC6L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:67,245,414...67,261,222
Ensembl chr X:67,245,414...67,280,756
|
|
G |
Eri2 |
ERI1 exoribonuclease family member 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ERI2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of ERRFI1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ERRFI1 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of ERRFI1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
increases expression |
ISO |
Coumestrol results in increased expression of ESCO2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306
|
|
G |
Espl1 |
extra spindle pole bodies like 1, separase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ESPL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of ESPL1 mRNA Coumestrol results in increased expression of ESPL1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression affects response to substance increases activity affects binding |
ISO EXP |
2,2-bis(4-glycidyloxyphenyl)propane analog inhibits the reaction [Coumestrol binds to ESR1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Coumestrol binds to ESR1 protein]; 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; [Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein; [Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA; Benzo(a)pyrene inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; bisphenol F diglycidyl ether analog inhibits the reaction [Coumestrol binds to ESR1 protein]; bisphenol F diglycidyl ether inhibits the reaction [Coumestrol binds to ESR1 protein]; CCND1 protein promotes the reaction [Coumestrol results in increased activity of ESR1 protein]; Coumestrol binds to and results in increased activity of ESR1 protein; Coumestrol inhibits the reaction [16 alpha-iodoestradiol binds to ESR1 protein]; Coumestrol inhibits the reaction [Estradiol binds to ESR1 protein]; Coumestrol promotes the reaction [NCOA2 protein binds to ESR1 protein]; Diethylstilbestrol inhibits the reaction [Coumestrol binds to ESR1 protein]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CCN5 mRNA]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of CXCL12 mRNA]; ESR1 protein inhibits the reaction [Coumestrol results in increased expression of PGR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA]; Estradiol inhibits the reaction [Coumestrol binds to ESR1 protein]; Fulvestrant inhibits the reaction [[Coumestrol binds to ESR1 protein] which results in increased activity of ALPL protein]; Fulvestrant inhibits the reaction [Coumestrol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [Coumestrol results in increased activity of ESR1 protein]; Tamoxifen promotes the reaction [Coumestrol results in increased activity of ESR1 protein mutant form]; tetrabromobisphenol A inhibits the reaction [Coumestrol binds to ESR1 protein modified form]; tetrachlorodian inhibits the reaction [Coumestrol binds to ESR1 protein modified form] Coumestrol results in decreased expression of ESR1 protein [Fulvestrant co-treated with Coumestrol] results in increased expression of ESR1 mRNA; Fulvestrant inhibits the reaction [Coumestrol results in decreased expression of ESR1 protein] ESR1 protein affects the susceptibility to Coumestrol Coumestrol binds to ESR1 protein; Coumestrol binds to ESR1 protein modified form |
CTD |
PMID:9048584 PMID:9751507 PMID:10397250 PMID:11162928 PMID:11518614 PMID:11867264 PMID:12650720 PMID:12765243 PMID:15084758 PMID:15876408 PMID:16118406 PMID:16328721 PMID:16566672 PMID:17174995 PMID:17275032 PMID:18310284 PMID:19400946 PMID:19913605 PMID:22562034 PMID:23384675 PMID:28396216 PMID:29152682 PMID:29162470 PMID:30143207 PMID:32619634 PMID:34848279 More...
|
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression affects binding affects response to substance increases activity |
ISO EXP IPI |
Coumestrol binds to and results in increased activity of ESR2 protein; Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ADRA2A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANLN mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ANP32E mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ASPM mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of AURKA mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of BIN3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CCNA2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDCA3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CENPF mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CLCC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CTNNAL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CXCL12 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DEPDC1B mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of DHRS2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMGB2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of HMMR mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IGFBP4 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL17RB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IL20 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of IRS1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KCNK5 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF18A mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MKI67 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of MYC mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NCAPG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NEK2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NPY1R mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of NUSAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDLIM3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PDZK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PIF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PKIB mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of PLK1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RACGAP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RASGRP1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of RERG mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SLC26A2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of SPC25 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of ST8SIA6 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of STC2 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TFF1 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TMPRSS3 mRNA]; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TRAF4 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN2C mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of CDKN3 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF14 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF15 mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of KIF20A mRNA]; ESR2 protein promotes the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of TOP2A mRNA] Coumestrol results in increased expression of ESR2 mRNA Coumestrol binds to Esr2 protein Coumestrol results in increased expression of ESR2 protein; Coumestrol results in increased expression of ESR2 protein alternative form ESR2 protein affects the susceptibility to Coumestrol ESR2 protein affects the reaction [Coumestrol results in increased expression of SOD2 protein] Coumestrol binds to ESR2 protein [Fulvestrant co-treated with Coumestrol] results in increased expression of ESR2 mRNA; Coumestrol inhibits the reaction [16 alpha-iodoestradiol binds to ESR2 protein]; Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein alternative form] Coumestrol results in increased activity of ESR2 protein |
CTD RGD |
PMID:9048584 PMID:9492041 PMID:9751507 PMID:11518614 PMID:12224631 PMID:12765243 PMID:15084758 PMID:16118406 PMID:16566672 PMID:17275032 PMID:18310284 PMID:19913605 PMID:21708076 PMID:23526725 PMID:27634370 PMID:34848279 PMID:9048584 PMID:9048584 More...
|
RGD:8694130, RGD:8694130 |
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esyt2 |
extended synaptotagmin 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ESYT2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590
|
|
G |
Etnk1 |
ethanolamine kinase 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of ETNK1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770
|
|
G |
Evi5 |
ecotropic viral integration site 5 |
decreases expression |
ISO |
Coumestrol results in decreased expression of EVI5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:1,875,601...2,021,678
Ensembl chr14:1,875,647...2,021,678
|
|
G |
Exo1 |
exonuclease 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of EXO1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EXO1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EXO1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Exoc2 |
exocyst complex component 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EXOC2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:33,506,289...33,698,246
Ensembl chr17:33,506,338...33,693,289
|
|
G |
Exosc2 |
exosome component 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of EXOSC2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:14,962,930...14,973,645
Ensembl chr 3:14,962,917...14,973,575
|
|
G |
Exosc3 |
exosome component 3 |
increases expression |
ISO |
Coumestrol results in increased expression of EXOSC3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:59,573,849...59,579,065
Ensembl chr 5:59,573,886...59,579,060
|
|
G |
Exosc8 |
exosome component 8 |
increases expression |
ISO |
Coumestrol results in increased expression of EXOSC8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
|
|
G |
Exosc9 |
exosome component 9 |
multiple interactions |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of EXOSC9 mRNA] |
CTD |
PMID:18310284 |
|
NCBI chr 2:119,416,028...119,426,981
Ensembl chr 2:119,388,715...119,427,051
|
|
G |
Ext1 |
exostosin glycosyltransferase 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EXT1 mRNA Coumestrol results in decreased expression of EXT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of EZH2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EZH2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of EZH2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EZR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
decreases expression |
ISO |
Coumestrol results in decreased expression of F2R mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of F2RL1 mRNA Coumestrol results in decreased expression of F2RL1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FABP5 mRNA] |
CTD |
PMID:18310284 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fads1 |
fatty acid desaturase 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of FADS1 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of FADS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fah |
fumarylacetoacetate hydrolase |
increases expression |
ISO |
Coumestrol results in increased expression of FAH mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
|
|
G |
Fam107b |
family with sequence similarity 107, member B |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM107B mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of FAM107B mRNA Coumestrol results in decreased expression of FAM107B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:74,478,608...74,685,027
Ensembl chr17:74,478,608...74,684,989
|
|
G |
Fam110b |
family with sequence similarity 110, member B |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM110B mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FAM110B mRNA Coumestrol results in decreased expression of FAM110B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:18,789,389...18,929,828
|
|
G |
Fam110c |
family with sequence similarity 110, member C |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of FAM110C mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of FAM110C mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:47,638,466...47,644,723
Ensembl chr 6:47,638,276...47,644,634
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FAM111A mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FAM111A mRNA Coumestrol results in increased expression of FAM111A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fam149b1 |
family with sequence similarity 149, member B1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM149B1 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of FAM149B1 mRNA Coumestrol results in decreased expression of FAM149B1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:3,929,190...3,967,140
Ensembl chr15:3,929,190...3,966,997
|
|
G |
Fam161b |
FAM161 centrosomal protein B |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of FAM161B mRNA [Coumestrol co-treated with resveratrol] results in decreased expression of FAM161B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:103,990,603...104,007,754
Ensembl chr 6:103,992,170...104,018,776
|
|
G |
Fam169a |
family with sequence similarity 169, member A |
decreases expression |
ISO |
Coumestrol results in decreased expression of FAM169A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:28,384,162...28,441,361
Ensembl chr 2:28,383,784...28,438,910
|
|
G |
Fam171b |
family with sequence similarity 171, member B |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of FAM171B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127
|
|
G |
Fam174b |
family with sequence similarity 174, member B |
decreases expression |
ISO |
Coumestrol results in decreased expression of FAM174B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:127,515,393...127,618,591
Ensembl chr 1:127,514,041...127,596,128 Ensembl chr 1:127,514,041...127,596,128
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
decreases expression |
ISO |
Coumestrol results in decreased expression of FAM210B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397
|
|
G |
Fam216a |
family with sequence similarity 216, member A |
increases expression |
ISO |
Coumestrol results in increased expression of FAM216A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:34,198,526...34,207,673
Ensembl chr12:34,198,526...34,207,665
|
|
G |
Fam222b |
family with sequence similarity 222, member B |
decreases expression |
ISO |
Coumestrol results in decreased expression of FAM222B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:62,986,571...63,052,350
Ensembl chr10:62,986,571...63,052,350
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM43A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FAM43A mRNA Coumestrol results in decreased expression of FAM43A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401
|
|
G |
Fanca |
FA complementation group A |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of FANCA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:51,304,126...51,362,586
Ensembl chr19:51,304,021...51,362,527
|
|
G |
Fancd2 |
FA complementation group D2 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of FANCD2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCD2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCD2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fancg |
FA complementation group G |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCG mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCG mRNA Coumestrol results in increased expression of FANCG mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029
|
|
G |
Fanci |
FA complementation group I |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCI mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCI mRNA Coumestrol results in increased expression of FANCI mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Fancl |
FA complementation group L |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCL mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FANCL mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255
|
|
G |
Farsb |
phenylalanyl-tRNA synthetase subunit beta |
increases expression |
ISO |
Coumestrol results in increased expression of FARSB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:79,887,852...79,947,082
Ensembl chr 9:79,887,842...79,947,045
|
|
G |
Fblim1 |
filamin binding LIM protein 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of FBLIM1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:153,883,945...153,915,524
Ensembl chr 5:153,883,960...153,913,757
|
|
G |
Fbxl5 |
F-box and leucine-rich repeat protein 5 |
decreases expression |
ISO |
Coumestrol results in decreased expression of FBXL5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:67,305,109...67,347,383
Ensembl chr14:67,267,801...67,347,383
|
|
G |
Fbxo38 |
F-box protein 38 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FBXO38 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:55,956,950...56,004,013
Ensembl chr18:55,956,959...56,003,961
|
|
G |
Fbxo5 |
F-box protein 5 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FBXO5 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FBXO5 mRNA Coumestrol results in increased expression of FBXO5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437
|
|
G |
Fcf1 |
Fcf1 rRNA-processing protein |
increases expression |
ISO |
Coumestrol results in increased expression of FCF1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:104,617,780...104,629,643
Ensembl chr 6:104,617,770...104,629,643
|
|
G |
Fcmr |
Fc mu receptor |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FCMR mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FCMR mRNA] |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr13:42,337,363...42,351,706
Ensembl chr13:42,337,414...42,351,653
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FDFT1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FDFT1 mRNA Coumestrol results in increased expression of FDFT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of FDPS mRNA Coumestrol results in increased expression of FDPS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of FEN1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FEN1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FEN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fermt2 |
FERM domain containing kindlin 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FERMT2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:18,682,927...18,751,959
Ensembl chr15:18,682,927...18,751,811
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of FGFR1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fh |
fumarate hydratase |
increases expression |
ISO |
Coumestrol results in increased expression of FH mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of FHL1 mRNA] |
CTD |
PMID:18310284 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of FHL2 mRNA Coumestrol results in increased expression of FHL2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fibp |
FGF1 intracellular binding protein |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIBP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:202,768,065...202,772,405
Ensembl chr 1:202,768,078...202,772,399
|
|
G |
Fignl1 |
fidgetin-like 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of FIGNL1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIGNL1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FIGNL1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FILIP1L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
|
|
G |
Firrm |
FIGNL1 interacting regulator of recombination and mitosis |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIRRM mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FIRRM mRNA Coumestrol results in increased expression of FIRRM mRNA |
CTD |
PMID:19167446 |
|
NCBI chr13:76,301,914...76,345,842
Ensembl chr13:76,301,918...76,345,804
|
|
G |
Fkbp11 |
FKBP prolyl isomerase 11 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FKBP11 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FKBP11 mRNA Coumestrol results in increased expression of FKBP11 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FKBP4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of FKBP4 mRNA Coumestrol results in increased expression of FKBP4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of FKBP5 mRNA Coumestrol results in increased expression of FKBP5 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fkbpl |
FKBP prolyl isomerase like |
increases expression |
ISO |
Coumestrol results in increased expression of FKBPL mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:4,099,845...4,101,315
Ensembl chr20:4,099,806...4,101,368
|
|
G |
Flcn |
folliculin |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of FLCN mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FLCN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769
|
|
G |
Fmnl2 |
formin-like 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of FMNL2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:37,348,791...37,624,746
Ensembl chr 3:37,348,574...37,624,754
|
|
G |
Fnbp1 |
formin binding protein 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FNBP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:14,309,067...14,424,378
Ensembl chr 3:14,309,640...14,424,881
|
|
G |
Fnbp1l |
formin binding protein 1-like |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FNBP1L mRNA Coumestrol results in decreased expression of FNBP1L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:210,647,241...210,748,203
Ensembl chr 2:210,647,246...210,738,455
|
|
G |
Fndc3b |
fibronectin type III domain containing 3B |
decreases expression |
ISO |
Coumestrol results in decreased expression of FNDC3B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:110,311,439...110,617,504
Ensembl chr 2:110,312,694...110,547,830
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxd1 |
forkhead box D1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of FOXD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:29,702,558...29,704,978
Ensembl chr 2:29,702,558...29,704,978
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FOXM1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of FOXM1 mRNA Coumestrol results in increased expression of FOXM1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOXO3 mRNA Coumestrol results in decreased expression of FOXO3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp2 |
forkhead box P2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOXP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
|
|
G |
Foxred2 |
FAD-dependent oxidoreductase domain containing 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of FOXRED2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:109,521,761...109,538,300
Ensembl chr 7:109,521,761...109,540,874
|
|
G |
Frmd3 |
FERM domain containing 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of FRMD3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:87,764,755...88,031,091
Ensembl chr 5:87,764,604...88,031,091
|
|
G |
Frmd6 |
FERM domain containing 6 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FRMD6 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of FRMD6 mRNA Coumestrol results in decreased expression of FRMD6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:89,345,983...89,419,579
Ensembl chr 6:89,346,035...89,419,579
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FSCN1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Ftsj1 |
FtsJ RNA 2'-O-methyltransferase 1 |
increases expression |
ISO |
Coumestrol results in increased expression of FTSJ1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:14,243,684...14,256,555
Ensembl chr X:14,244,050...14,252,030
|
|
G |
Fuca1 |
alpha-L-fucosidase 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of FUCA1 mRNA Coumestrol results in decreased expression of FUCA1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:148,152,718...148,169,972
Ensembl chr 5:148,152,700...148,169,972
|
|
G |
Fv1 |
Friend virus susceptibility 1 |
increases expression |
ISO |
Coumestrol results in increased expression of C19ORF48P mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:94,730,839...94,736,791
Ensembl chr 1:94,730,606...94,737,594
|
|
G |
Fyb2 |
FYN binding protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of FYB2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:119,677,116...119,800,911
Ensembl chr 5:119,677,204...119,800,910
|
|
G |
Fyco1 |
FYVE and coiled-coil domain autophagy adaptor 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FYCO1 mRNA Coumestrol results in decreased expression of FYCO1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021
|
|
G |
Fzd2 |
frizzled class receptor 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of FZD2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
|
|
G |
G2e3 |
G2/M-phase specific E3 ubiquitin protein ligase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G2E3 mRNA Coumestrol results in increased expression of G2E3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:68,763,847...68,795,305
Ensembl chr 6:68,764,185...68,793,924
|
|
G |
G3bp2 |
G3BP stress granule assembly factor 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G3BP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:15,932,403...16,020,555
Ensembl chr14:15,987,417...16,020,548
|
|
G |
Gabpb2 |
GA binding protein transcription factor subunit beta 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GABPB2 mRNA Coumestrol results in increased expression of GABPB2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:182,755,304...182,795,368
Ensembl chr 2:182,761,359...182,795,109
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of GADD45A mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GADD45A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45gip1 |
GADD45G interacting protein 1 |
increases expression |
ISO |
Coumestrol results in increased expression of GADD45GIP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:23,320,662...23,323,211
Ensembl chr19:23,320,159...23,323,236
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
ISO |
[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GAL mRNA] |
CTD |
PMID:18310284 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Galns |
galactosamine (N-acetyl)-6-sulfatase |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:50,628,639...50,662,477
Ensembl chr19:50,628,552...50,662,246
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT10 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GALNT10 mRNA Coumestrol results in decreased expression of GALNT10 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013
|
|
G |
Galnt7 |
polypeptide N-acetylgalactosaminyltransferase 7 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT7 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GALNT7 mRNA Coumestrol results in decreased expression of GALNT7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690
|
|
G |
Ganab |
glucosidase II alpha subunit |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GANAB mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695
|
|
G |
Gart |
phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase |
increases expression |
ISO |
Coumestrol results in increased expression of GART mRNA |
CTD |
PMID:19167446 |
|
NCBI chr11:30,864,896...30,891,125
Ensembl chr11:30,865,889...30,891,125
|
|
G |
Gas2l3 |
growth arrest-specific 2 like 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GAS2L3 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of GAS2L3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:23,803,578...23,836,816
Ensembl chr 7:23,806,310...23,836,411
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GATA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression |
ISO |
Coumestrol results in decreased expression of GATA3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gatad1 |
GATA zinc finger domain containing 1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of GATAD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:30,507,530...30,519,107
Ensembl chr 4:30,507,538...30,519,107
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GBP2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GCHFR mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GCHFR mRNA Coumestrol results in increased expression of GCHFR mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:106,158,046...106,162,080
Ensembl chr 3:106,159,394...106,162,080
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of GCLM mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GDF15 mRNA Coumestrol results in decreased expression of GDF15 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GDPD3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GDPD3 mRNA Coumestrol results in decreased expression of GDPD3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
increases expression |
ISO |
Coumestrol results in increased expression of GEM mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222
|
|
G |
Gemin2 |
gem (nuclear organelle) associated protein 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GEMIN2 mRNA Coumestrol results in increased expression of GEMIN2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:76,706,424...76,721,154
Ensembl chr 6:76,707,523...76,721,153
|
|
G |
Gemin4 |
gem (nuclear organelle) associated protein 4 |
increases expression |
ISO |
Coumestrol results in increased expression of GEMIN4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:61,062,420...61,073,529
Ensembl chr10:61,066,425...61,073,431 Ensembl chr10:61,066,425...61,073,431
|
|
G |
Gemin6 |
gem (nuclear organelle) associated protein 6 |
increases expression |
ISO |
Coumestrol results in increased expression of GEMIN6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:14,786,090...14,790,617
Ensembl chr 6:14,786,070...14,790,612
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of GFRA1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GFRA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GFRA1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Gga2 |
golgi associated, gamma adaptin ear containing, ARF binding protein 2 |
increases expression |
ISO |
Coumestrol results in increased expression of GGA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:176,552,046...176,585,332
Ensembl chr 1:176,552,046...176,585,361
|
|
G |
Ggct |
gamma-glutamyl cyclotransferase |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GGCT mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277
|
|
G |
Ggh |
gamma-glutamyl hydrolase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GGH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GGH mRNA Coumestrol results in increased expression of GGH mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787
|
|
G |
Gins1 |
GINS complex subunit 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS1 mRNA Coumestrol results in increased expression of GINS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:139,724,513...139,745,930
Ensembl chr 3:139,724,490...139,745,936
|
|
G |
Gins2 |
GINS complex subunit 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS2 mRNA Coumestrol results in increased expression of GINS2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339
|
|
G |
Gins3 |
GINS complex subunit 3 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS3 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GINS3 mRNA Coumestrol results in increased expression of GINS3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr19:9,420,085...9,428,621
Ensembl chr19:9,420,086...9,428,687
|
|
G |
Gins4 |
GINS complex subunit 4 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:68,787,572...68,799,938
Ensembl chr16:68,767,339...68,802,273
|
|
G |
Gla |
galactosidase, alpha |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of GLA mRNA Coumestrol results in increased expression of GLA mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664
|
|
G |
Gle1 |
GLE1 RNA export mediator |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of GLE1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GLE1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:13,209,312...13,237,018
Ensembl chr 3:13,209,322...13,237,379
|
|
G |
Glmn |
glomulin, FKBP associated protein |
increases expression |
ISO |
Coumestrol results in increased expression of GLMN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:2,187,144...2,231,295
Ensembl chr14:2,187,642...2,230,420
|
|
G |
Glmp |
glycosylated lysosomal membrane protein |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of GLMP mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:173,794,273...173,797,863
Ensembl chr 2:173,794,255...173,799,960
|
|
G |
Gls |
glutaminase |
decreases expression |
ISO |
Coumestrol results in decreased expression of GLS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gmnn |
geminin, DNA replication inhibitor |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GMNN mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GMNN mRNA Coumestrol results in increased expression of GMNN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
|
|
G |
Gmps |
guanine monophosphate synthase |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GMPS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
decreases expression |
ISO |
Coumestrol results in decreased expression of GNAI1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnaq |
G protein subunit alpha q |
decreases expression |
ISO |
Coumestrol results in decreased expression of GNAQ mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672
|
|
G |
Gnl3l |
G protein nucleolar 3 like |
decreases expression |
ISO |
Coumestrol results in decreased expression of GNL3L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:19,961,277...19,994,454
Ensembl chr X:19,958,603...19,994,508
|
|
G |
Gns |
glucosamine (N-acetyl)-6-sulfatase |
decreases expression |
ISO |
Coumestrol results in decreased expression of GNS mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:56,889,148...56,923,173
Ensembl chr 7:56,889,232...56,923,151
|
|
G |
Golga2 |
golgin A2 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of GOLGA2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GOLGA2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:15,583,862...15,604,279
Ensembl chr 3:15,584,039...15,604,279
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of GOT1 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GOT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpaa1 |
glycosylphosphatidylinositol anchor attachment 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPAA1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPAA1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484
|
|
G |
Gpat4 |
glycerol-3-phosphate acyltransferase 4 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPAT4 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPAT4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr16:68,819,031...68,852,903
Ensembl chr16:68,819,079...68,852,901
|
|
G |
Gpatch11 |
G patch domain containing 11 |
increases expression |
ISO |
Coumestrol results in increased expression of GPATCH11 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:16,229,933...16,243,305
Ensembl chr 6:16,233,059...16,243,238
|
|
G |
Gpatch2l |
G patch domain containing 2-like |
decreases expression |
ISO |
Coumestrol results in decreased expression of GPATCH2L mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888
|
|
G |
Gpatch4 |
G patch domain containing 4 |
increases expression |
ISO |
Coumestrol results in increased expression of GPATCH4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:173,499,700...173,520,346
Ensembl chr 2:173,509,897...173,518,684
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
increases expression |
ISO |
Coumestrol results in increased expression of GPD2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of GPER1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889
|
|
G |
Gpr137b |
G protein-coupled receptor 137B |
decreases expression |
ISO |
Coumestrol results in decreased expression of GPR137B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:86,003,635...86,041,841
Ensembl chr17:85,966,921...86,041,835
|
|
G |
Gpr160 |
G protein-coupled receptor 160 |
decreases expression |
ISO |
Coumestrol results in decreased expression of GPR160 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:112,483,364...112,563,072
Ensembl chr 2:112,484,935...112,563,148
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GPRC5A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GPRC5A mRNA Coumestrol results in decreased expression of GPRC5A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260
|
|
G |
Gprc5c |
G protein-coupled receptor, class C, group 5, member C |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of GPRC5C mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GPRC5C mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926
|
|
G |
Gpsm2 |
G-protein signaling modulator 2 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GPSM2 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GPSM2 mRNA] Coumestrol results in increased expression of GPSM2 mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154
|
|
G |
Gpx8 |
glutathione peroxidase 8 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of GPX8 mRNA [Coumestrol co-treated with resveratrol] results in increased expression of GPX8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:44,676,448...44,680,042
Ensembl chr 2:44,676,454...44,680,195
|
|
G |
Gramd1a |
GRAM domain containing 1A |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GRAMD1A mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GRAMD1A mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 1:86,367,001...86,393,348
Ensembl chr 1:86,367,001...86,393,336
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
decreases expression |
ISO |
Coumestrol results in decreased expression of GRB10 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806
|
|
G |
Greb1 |
growth regulating estrogen receptor binding 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GREB1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GREB1 mRNA] Coumestrol results in increased expression of GREB1 mRNA |
CTD |
PMID:18310284 PMID:19167446 PMID:35307500 |
|
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
|
|
G |
Grhl3 |
grainyhead-like transcription factor 3 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GRHL3 mRNA; [Coumestrol co-treated with resveratrol] results in decreased expression of GRHL3 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 5:147,774,161...147,806,291
Ensembl chr 5:147,774,160...147,806,160
|
|
G |
Grk6 |
G protein-coupled receptor kinase 6 |
increases expression |
ISO |
Coumestrol results in increased expression of GRK6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644
|
|
G |
Grn |
granulin precursor |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in decreased expression of GRN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
increases expression |
ISO |
Coumestrol results in increased expression of GRPEL1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:74,292,023...74,298,243
Ensembl chr14:74,292,023...74,298,200
|
|
G |
Gtf2h4 |
general transcription factor 2H subunit 4 |
increases expression |
ISO |
Coumestrol results in increased expression of GTF2H4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984
|
|
G |
Gtf2ird1 |
GTF2I repeat domain containing 1 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GTF2IRD1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr12:22,254,113...22,361,052
Ensembl chr12:22,254,221...22,361,040
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of GTSE1 mRNA; ESR2 protein affects the reaction [[Coumestrol co-treated with ESR1 protein] results in increased expression of GTSE1 mRNA] Coumestrol results in increased expression of GTSE1 mRNA |
CTD |
PMID:18310284 PMID:19167446 |
|
NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806
|
|
G |
Gulp1 |
GULP PTB domain containing engulfment adaptor 1 |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GULP1 mRNA Coumestrol results in decreased expression of GULP1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
multiple interactions decreases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H1-2 mRNA Coumestrol results in decreased expression of H1-2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635
|
|
G |
H2ac25 |
H2A clustered histone 25 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2AC25 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AX mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of H2AX mRNA Coumestrol results in increased expression of H2AX mRNA; Coumestrol results in increased expression of H2AX protein modified form |
CTD |
PMID:19167446 PMID:28986287 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
H2az1 |
H2A.Z variant histone 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AZ1 mRNA; [Coumestrol co-treated with Resveratrol] results in increased expression of H2AZ1 mRNA Coumestrol results in increased expression of H2AZ1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:226,355,668...226,357,984
Ensembl chr 2:226,355,708...226,358,485
|
|
G |
H2az2 |
H2A.Z variant histone 2 |
increases expression multiple interactions |
ISO |
Coumestrol results in increased expression of H2AZ2 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AZ2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr14:81,293,304...81,312,209
Ensembl chr14:81,293,299...81,312,144 Ensembl chr 4:81,293,299...81,312,144 Ensembl chr16:81,293,299...81,312,144
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression |
ISO |
Coumestrol results in decreased expression of H2BC12 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:42,485,699...42,486,162
|
|
G |
H2bc6 |
H2B clustered histone 6 |
decreases expression |
ISO |
Coumestrol results in decreased expression of H2BC6 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:41,520,775...41,521,238
|
|
G |
H2bc8 |
H2B clustered histone 8 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of H2BC8 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC8 mRNA; [Coumestrol co-treated with Resveratrol] results in decreased expression of H2BC8 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:42,708,658...42,709,408
|
|
G |
H2bc9 |
H2B clustered histone 9 |
decreases expression multiple interactions |
ISO |
Coumestrol results in decreased expression of H2BC9 mRNA [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC9 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr17:42,470,593...42,478,590
|
|
G |
H3f3b |
H3.3 histone B |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H3-3B mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:101,256,484...101,258,716
Ensembl chr10:101,256,480...101,258,709 Ensembl chr13:101,256,480...101,258,709
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HADH mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HADH mRNA Coumestrol results in increased expression of HADH mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Haspin |
histone H3 associated protein kinase |
multiple interactions |
ISO |
[Coumestrol co-treated with resveratrol] results in increased expression of HASPIN mRNA |
CTD |
PMID:19167446 |
|
NCBI chr10:57,747,731...57,750,518
Ensembl chr10:57,747,573...57,750,512
|
|
G |
Hat1 |
histone acetyltransferase 1 |
increases expression |
ISO |
Coumestrol results in increased expression of HAT1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
|
|
G |
Haus1 |
HAUS augmin-like complex, subunit 1 |
multiple interactions increases expression |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HAUS1 mRNA; [Coumestrol co-treated with resveratrol] results in increased expression of HAUS1 mRNA Coumestrol results in increased expression of HAUS1 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr18:71,275,417...71,286,626
Ensembl chr18:71,273,537...71,286,660
|
|
G |
Haus2 |
HAUS augmin like complex subunit 2 |
decreases expression |
ISO |
Coumestrol results in decreased expression of HAUS2 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr 3:107,553,146...107,565,982
Ensembl chr 3:107,553,161...107,565,157
|
|
G |
Haus4 |
HAUS augmin-like complex, subunit 4 |
multiple interactions |
ISO |
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HAUS4 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr15:27,994,530...28,006,147
Ensembl chr15:27,994,532...28,005,938
|
|
G |
Haus7 |
HAUS augmin-like complex, subunit 7 |
increases expression |
ISO |
Coumestrol results in increased expression of HAUS7 mRNA |
CTD |
PMID:19167446 |
|
NCBI chr X:151,154,979...151,174,441
Ensembl chr X:151,154,979...151,180,577
|
|
G |
Haus8 |
HAUS augmin-like complex, subunit 8 |
increases ex |